Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mirum Pharmaceuticals Inc. (MIRM:NASDAQ), powered by AI.
Mirum Pharmaceuticals Inc. is currently trading at $101.55. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Mirum Pharmaceuticals Inc. on Alpha Lenz.
Mirum Pharmaceuticals Inc.'s P/E ratio is -218.2.
“Mirum Pharmaceuticals Inc. trades at a P/E of -218.2 (undervalued) with modest ROE of -8.6%. 3Y revenue CAGR of 89.1% highlights clear growth momentum.”
Ask for details →Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. Its primary objective is to address unmet medical needs, particularly in the sphere of liver diseases where few treatment options exist. Mirum is especially recognized for its work on conditions like Alagille syndrome, a rare genetic disorder affecting the liver, heart, and other parts of the body. The company is committed to advancing its research to offer novel solutions, facilitating regulatory approval processes, and ensuring global access to its therapies. Mirum Pharmaceuticals plays an essential role in the healthcare sector, providing essential treatment options that can significantly improve the quality of life for patients with chronic and challenging illnesses. Its contributions are vital for advancements in the understanding and management of complex liver diseases, making it a key player in the biopharmaceutical landscape, serving the needs of niche patient populations with precision medicine.
“Mirum Pharmaceuticals Inc. trades at a P/E of -218.2 (undervalued) with modest ROE of -8.6%. 3Y revenue CAGR of 89.1% highlights clear growth momentum.”
Ask for details →Mirum Pharmaceuticals Inc. (ticker: MIRM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 349 employees. Market cap is $5.1B.
The current price is $101.55 with a P/E ratio of -218.19x and P/B of 16.2x.
ROE is -8.65% and operating margin is -4.25%. Annual revenue is $521M.